ANI Pharmaceuticals, Inc. (ANIP) vs BioCryst Pharmaceuticals, Inc. (BCRX)
- ANI Pharmaceuticals, Inc. ANIP 72.08 −0.28%
- BioCryst Pharmaceuticals, Inc. BCRX 7.79 −2.87%
ANI Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.1B against $1.7B — 1.2× the size. BioCryst Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 14.9×. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 30.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.0% vs −40.9%) and the higher return on invested capital (11.3% vs −610.6%). Across the 18 metrics below, ANI Pharmaceuticals, Inc. leads on 9 and BioCryst Pharmaceuticals, Inc. on 9.
Valuation
Profitability
| Metric | ANIP | BCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 60.40% | 97.78% | 53.94% |
| Operating margin | 15.37% | (33.29%) | 0.00% |
| Net margin | 11.04% | (40.90%) | 0.00% |
| Free cash flow margin | 17.12% | 39.75% | 0.00% |
| Return on equity | 20.88% | 87.84% | (0.40%) |
| Return on assets | 7.61% | (75.79%) | (3.32%) |
| Return on invested capital | 11.30% | (610.55%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack